CHENGDU, China, Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, November 11th, 2008. The Conference will be held on November 10th-12th at New York Palace Hotel in New York City.
The Company's presentation will take place in the Henry Salon (5th Floor) at 12:00 p.m. EST. Dr. Guoqing Jiang, Tianyin's Chairman and CEO, Mr. Allen Tang, assistant to the CEO, and Mr. Stewart Lor, a member of the Board of Directors, will be representing Tianyin at the conference and will be available for one-on-one meetings with analysts and investors throughout the day.
Management will discuss the Company's current product portfolio, development pipeline, research and development platform, recent financial highlights and its long term growth strategy.
Participation is by invitation and registration is mandatory. For more information on the conference contact your Rodman & Renshaw representative or visit http://www.rodmanandrenshaw.com.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 48 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,384 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com
Safe Harbor Statement
This Press Release contains or may contain forward looking statements
and information that are based upon beliefs of and information currently
available to the Company's management as well as estimates and assumptions
made by the Company's management. When used herein the words "anticipate",
"believe", "estimate", "expect", "future", "intend", "plan" and similar
expressions as they relate to the Company or the Company's management
identify forward looking statements. These statements involve certain risks
and uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of
economic conditions and other uncertainties detailed in the Company's
filings with the Securities and Exchange Commission. Should one or more of
these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from
those anticipated, believed, estimated, intended or planned.
For more information, please contact:
For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
HC International, Inc.
US (914) 669-0222
|SOURCE Tianyin Pharmaceutical (TPI)|
Copyright©2008 PR Newswire.
All rights reserved